Evolution of pseudomonas aeruginosa virulence as a result of phage predation

Applied and Environmental Microbiology

Volumn 79, Issue 19, 2013, Pages 6110-6116

  Hosseinidoust, Zeinab ^a   van de Ven, Theo G M ^a   Tufenkji, Nathalie ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC-RESISTANT BACTERIA; BACTERIAL INFECTIONS; EXPERIMENTAL EVOLUTION; HUMAN KERATINOCYTES; METABOLIC ACTION; MURINE MACROPHAGES; PSEUDOMONAS AERUGINOSA; VIRULENCE FACTORS;

ANTIGEN-ANTIBODY REACTIONS; BACTERIA; POLYMERASE CHAIN REACTION; TRANSCRIPTION;

BACTERIOPHAGES;

ANCESTRY; ANTIBIOTIC RESISTANCE; BACTERIAL DISEASE; BACTERIOPHAGE; BACTERIUM; BIOTECHNOLOGY; DISEASE TREATMENT; EMERGENCE; EVOLUTIONARY BIOLOGY; GENE EXPRESSION; PREDATION; RODENT; VIRULENCE;

VIRULENCE FACTOR;

ANIMAL; ARTICLE; BACTERIOPHAGE; CELL LINE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; IMMUNOLOGY; KERATINOCYTE; MACROPHAGE; METABOLISM; MICROBIOLOGY; MOUSE; MUTATION; PATHOGENICITY; PHAGOCYTOSIS; PHYSIOLOGY; PSEUDOMONAS AERUGINOSA; REAL TIME POLYMERASE CHAIN REACTION; VIROLOGY; VIRULENCE;

ANIMALS; BACTERIOPHAGES; CELL LINE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, BACTERIAL; HUMANS; KERATINOCYTES; MACROPHAGES; MICE; MUTATION; PHAGOCYTOSIS; PSEUDOMONAS AERUGINOSA; REAL-TIME POLYMERASE CHAIN REACTION; VIRULENCE; VIRULENCE FACTORS;

EID: 84884175953     PISSN: 00992240     EISSN: 10985336     Source Type: Journal    
DOI: 10.1128/AEM.01421-13     Document Type: Article

References (54)

1. Chastre J, Fagon JY. 2002. Ventilator-associated pneumonia. Am. J. Respir. Crit. Care Med. 165:867-903.
2. Mowat E, Paterson S, Fothergill JL, Wright EA, Ledson MJ, Walshaw MJ, Brockhurst MA, Winstanley C. 2011. Pseudomonas aeruginosa population diversity and turnover in cystic fibrosis chronic infections. Am. J. Respir. Crit. Care Med. 183:1674-1679.
3. Goldberg JB. 2010. Why is Pseudomonas aeruginosa a pathogen? F1000 Biol. Rep. 2:29. doi:10.3410/B2-29.
4. Wu DC, Chan WW, Metelitsa AI, Fiorillo L, Lin AN. 2011. Pseudomonas skin infection clinical features, epidemiology, and management. Am. J. Clin. Dermatol. 12:157-169.
5. Seth AK, Geringer MR, Gurjala AN, Hong SJ, Galiano RD, Leung KP, Mustoe TA. 2012. Treatment of Pseudomonas aeruginosa biofilm-infected wounds with clinical wound care strategies: a quantitative study using an in vivo rabbit ear model. Plast. Reconstr. Surg. 129:262e-274e. doi:10.1097/PRS.0b013e31823aeb3b.
6. Zhu H, Thuruthyil SJ, Willcox MDP. 2002. Determination of quorumsensing signal molecules and virulence factors of Pseudomonas aeruginosa isolates from contact lens-induced microbial keratitis. J. Med. Microbiol. 51:1063-1070.
7. Kipnis E, Sawa T, Wiener-Kronish J. 2006. Targeting mechanisms of Pseudomonas aeruginosa pathogenesis. Med. Mal. Infect. 36:78-91.
8. Levin BR, Bull JJ. 2004. Population and evolutionary dynamics of phage therapy. Nat. Rev. Microbiol. 2:166-173.
9. Heo YJ, Lee YR, Jung HH, Lee J, Ko G, Cho YH. 2009. Antibacterial efficacy of phages against Pseudomonas aeruginosa infections in mice and Drosophila melanogaster. Antimicrob. Agents Chemother. 53:2469-2474.
10. McVay CS, Velásquez M, Fralick JA. 2007. Phage therapy of Pseudomonas aeruginosa infection in a mouse burn wound model. Antimicrob. Agents Chemother. 51:1934-1938.
11. Soothill J, Hawkins C, Anggard E, Harper D. 2004. Therapeutic use of bacteriophages. Lancet Infect. Dis. 4:544-545.
12. Debarbieux L, Leduc D, Maura D, Morello E, Criscuolo A, Grossi O, Balloy V, Touqui L. 2010. Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections. J. Infect. Dis. 201:1096-1104.
13. Marza JA, Soothill JS, Boydell P, Collyns TA. 2006. Multiplication of therapeutically administered bacteriophages in Pseudomonas aeruginosa infected patients. Burns 32:644-646.
14. Merabishvili M, Pirnay JP, Verbeken G, Chanishvili N, Tediashvili M, Lashkhi N, Glonti T, Krylov V, Mast J, Van Parys L, Lavigne R, Volckaert G, Mattheus W, Verween G, De Corte P, Rose T, Jennes S, Zizi M, De Vos D, Vaneechoutte M. 2009. Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One 4:e4944. doi:10.1371/journal.pone.0004944.
15. Wright A, Hawkins CH, Änggård EE, Harper DR. 2009. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa: a preliminary report of efficacy. Clin. Otolaryngol. 34:349-357.
16. Comeau AM, Krisch HM. 2005. War is peace-dispatches from the bacterial and phage killing fields. Curr. Opin. Microbiol. 8:488-494.
17. Rice SA, Tan CH, Mikkelsen PJ, Kung V, Woo J, Tay M, Hauser A, McDougald D, Webb JS, Kjelleberg S. 2009. The biofilm life cycle and virulence of Pseudomonas aeruginosa are dependent on a filamentous prophage. ISME J. 3:271-282.
18. Brockhurst MA, Buckling A, Rainey PB. 2005. The effect of a bacteriophage on diversification of the opportunistic bacterial pathogen, Pseudomonas aeruginosa. Proc. Biol. Sci. 272:1385-1391.
19. Hosseinidoust Z, Tufenkji N, van de Ven TGM. 2013. Predation in homogeneous and heterogeneous phage environments affects virulence determinants of Pseudomonas aeruginosa. Appl. Environ. Microbiol. 79: 2862-2871.
20. Mizoguchi K, Morita M, Fischer CR, Yoichi M, Tanji Y, Unno H. 2003. Coevolution of bacteriophage PP01 and Escherichia coli O157:H7 in continuous culture. Appl. Environ. Microbiol. 69:170-176.
21. Drake D, Montie TC. 1988. Flagella, motility and invasive virulence of Pseudomonas aeruginosa. J. Gen. Microbiol. 134:43-52.
22. Galloway DR. 1991. Pseudomonas aeruginosa elastase and elastolysis revisited: recent developments. Mol. Microbiol. 5:2315-2321.
23. König B, Jaeger KE, Sage AE, Vasil ML, König W. 1996. Role of Pseudomonas aeruginosa lipase in inflammatory mediator release from human inflammatory effector cells (platelets, granulocytes, and monocytes). Infect. Immun. 64:3252-3258.
24. Shi W, Sun H. 2002. Type IV pilus-dependent motility and its possible role in bacterial pathogenesis. Infect. Immun. 70:1-4.
25. Hentzer M, Wu H, Andersen JB, Riedel K, Rasmussen TB, Bagge N, Kumar N, Schembri MA, Song Z, Kristoffersen P, Manefield M, Costerton JW, Molin S, Eberl L, Steinberg P, Kjelleberg S, Hoiby N, Givskov M. 2003. Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors. EMBO J. 22:3803-3815.
26. Friman VP, Hiltunen T, Jalasvuori M, Lindstedt C, Laanto E, Ö rmÄlÄ AM, Laakso J, Mappes J, Bamford JKH. 2011. High temperature and bacteriophages can indirectly select for bacterial pathogenicity in environmental reservoirs. PLoS One 6:e17651. doi:10.1371/journal.pone.0017651.
27. Holloway BW. 1955. Genetic recombination in Pseudomonas aeruginosa. J. Gen. Microbiol. 13:572-581.
28. Tang P, Foubister V, Pucciarelli MG, Finlay BB. 1993. Methods to study bacterial invasion. J. Microbiol. Methods 18:227-240.
29. Goldova J, Ulrych A, Hercik K, Branny P. 2011. A eukaryotic-type signalling system of Pseudomonas aeruginosa contributes to oxidative stress resistance, intracellular survival and virulence. BMC Genomics 12: 437. doi:10.1186/1471-2164-12-437.
30. Slater TF, Sawyer B, Sträuli U. 1963. Studies on succinate-tetrazolium reductase systems. III. Points of coupling of four different tetrazolium salts. Biochim. Biophys. Acta 77:383-393.
31. Gerhardt P, Murray RGE, Wood WA, Krieg NR (ed). 1994. Methods for general and molecular bacteriology. American Society for Microbiology, Washington, DC.
32. Huber B, Riedel K, Hentzer M, Heydorn A, Gotschlich A, Givskov M, Molin S, Eberl L. 2001. The cep quorum-sensing system of Burkholderia cepacia H111 controls biofilm formation and swarming motility. Microbiology 147:2517-2528.
33. Sbarra AJ, Gilfillan RF, Bardawil WA. 1960. A plate assay for elastase. Nature 188:322-323.
34. Habermann E, Hardt KL. 1972. A sensitive and specific plate test for the quantitation of phospholipases. Anal. Biochem. 50:163-173.
35. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2CT method. Methods 25: 402-408.
36. Matsumoto K. 2004. Role of bacterial proteases in pseudomonal and serratial keratitis. Biol. Chem. 385:1007-1016.
37. Heck LW, Morihara K, McRae WB, Miller EJ. 1986. Specific cleavage of human type III and IV collagens by Pseudomonas aeruginosa elastase. Infect. Immun. 51:115-118.
38. Azghani AO. 1996. Pseudomonas aeruginosa and epithelial permeability: role of virulence factors elastase and exotoxin A. Am. J. Respir. Cell Mol. Biol. 15:132-140.
39. Kon Y, Tsukada H, Hasegawa T, Igarashi K, Wada K, Suzuki E, Arakawa M, Gejyo F. 1999. The role of Pseudomonas aeruginosa elastase as a potent inflammatory factor in a rat air pouch inflammation model. FEMS Immunol. Med. Microbiol. 25:313-321.
40. Mariencheck WI, Alcorn JF, Palmer SM, Wright JR. 2003. Pseudomonas aeruginosa elastase degrades surfactant proteins A and D. Am. J. Respir. Cell Mol. Biol. 28:528-537.
41. Wretlind B, Pavlovskis OR. 1983. Pseudomonas aeruginosa elastase and its role in pseudomonas infections. Rev. Infect. Dis. 5(Suppl 5):S998-S1004.
42. Malloy JL, Veldhuizen RAW, Thibodeaux BA, O'Callaghan RJ, Wright JR. 2005. Pseudomonas aeruginosa protease IV degrades surfactant proteins and inhibits surfactant host defense and biophysical functions. Am. J. Physiol. Lung Cell. Mol. Physiol. 288:L409-L418.
43. Shaver CM, Hauser AR. 2004. Relative contributions of Pseudomonas aeruginosa ExoU, ExoS, and ExoT to virulence in the lung. Infect. Immun. 72:6969-6977.
44. Epelman S, Stack D, Bell C, Wong E, Neely GG, Krutzik S, Miyake K, Kubes P, Zbytnuik LD, Ma LL, Xie X, Woods DE, Mody CH. 2004. Different domains of Pseudomonas aeruginosa exoenzyme S activate distinct TLRs. J. Immunol. 173:2031-2040.
45. Lee VT, Smith RS, Tümmler B, Lory S. 2005. Activities of Pseudomonas aeruginosa effectors secreted by the type III secretion system in vitro and during infection. Infect. Immun. 73:1695-1705.
46. He SY, Nomura K, Whittam TS. 2004. Type III protein secretion mechanism in mammalian and plant pathogens. Biochim. Biophys. Acta 1694: 181-206.
47. Simpson DA, Speert DP. 2000. RpmA is required for nonopsonic phagocytosis of Pseudomonas aeruginosa. Infect. Immun. 68:2493-2502.
48. Amiel E, Lovewell RR, O'Toole GA, Hogan DA, Berwin B. 2010. Pseudomonas aeruginosa evasion of phagocytosis is mediated by loss of swimming motility and is independent of flagellum expression. Infect. Immun. 78:2937-2945.
49. Rodríguez-Rojas A, Mena A, Martín S, Borrell N, Oliver A, Blázquez J. 2009. Inactivation of the hmgA gene of Pseudomonas aeruginosa leads to pyomelanin hyperproduction, stress resistance and increased persistence in chronic lung infection. Microbiology 155:1050-1057.
50. Chang W, Small DA, Toghrol F, Bentley WE. 2005. Microarray analysis of Pseudomonas aeruginosa reveals induction of pyocin genes in response to hydrogen peroxide. BMC Genomics 6:115. doi:10.1186/1471-2164-6-115.
51. Casadevall A, Pirofski LA. 1999. Host-pathogen interactions: redefining the basic concepts of virulence and pathogenicity. Infect. Immun. 67: 3703-3713.
52. Coetzee JN, Hawtrey AO. 1962. A change in phenotype associated with the bacteriophage carrier state in a strain of Proteus mirabilis. Nature 194: 1196-1197. (Letter.)
53. Smith HW, Huggins MB. 1983. Effectiveness of phages in treating experimental Escherichia coli diarrhoea in calves, piglets and lambs. J. Gen. Microbiol. 129:2659-2675.
54. Scott AE, Timms AR, Connerton PL, Loc Carrillo C, Adzfa Radzum K, Connerton IF. 2007. Genome dynamics of Campylobacter jejuni in response to bacteriophage predation. PLoS Pathog. 3:e119. doi:10.1371/journal.ppat.0030119.